MUSC Cardiology
C

A New Era in Renal Protection in Cardiometabolic Disease

By MUSC Cardiology FEATURING Chakradhari Inampudi
By MUSC Cardiology FEATURING Chakradhari Inampudi
215 views
March 26, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
34:49
Scripps Health

Medications for Weight Loss: The New Satiety Hormones

Feat. K. Fujioka
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

37:21
University of Colorado Department of Medicine

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

Feat. R. Johnson
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
26:32
Practical Ways to Achieve Targets in Diabetes Care

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Feat. S. Nissen
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

26:49
Diana Isaacs

Tirzepatide Updates

44:41
Norman Lepor

Obesity: New Understanding and Treatments

06:31
Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

05:08
Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

36:34
Scripps Health

GLP-1 Hysteria

Feat. S. Harris
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim